Interleukin 1β inhibits CAR-induced expression of hepatic genes involved in drug and bilirubin clearance

Hepatology

Volumn 40, Issue 4, 2004, Pages 951-960

  Assenat, Eric ^a   Gerbal Chaloin, Sabine ^b   Larrey, Dominique ^a   Saric, Jean ^c   Fabre, Jean Michel ^a   Maurel, Patrick ^d   Vilarem, Marie José ^d   Pascussi, Jean Marc ^d  

^a HÔPITAL SAINT ELOI   (France)

^b Centre National de la Recherche Scientifique   (France)

^c HÔPITAL SAINT ANDRÉ   (France)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CARRIER PROTEIN; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450 2B; CYTOCHROME P450 3A; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; GLUCURONOSYLTRANSFERASE; HISTONE H4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; IRON TRANSPORT PROTEIN SLC21A6; LIPOPOLYSACCHARIDE; MESSENGER RNA; PHENOBARBITAL; PYRROLIDINE DITHIOCARBAMATE; TRANSCRIPTION FACTOR RELA; UDP GLUCURONYLTRANSFERASE 1A1; UNCLASSIFIED DRUG; XENOBIOTIC AGENT; CELL RECEPTOR; GLUCOCORTICOID; HISTONE; INTERLEUKIN 1; TRANSCRIPTION FACTOR;

ACETYLATION; ARTICLE; BILIRUBIN METABOLISM; CELL STRAIN HEPG2; CHROMATIN; DRUG METABOLISM; ENZYME INDUCTION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HELA CELL; HUMAN; HUMAN CELL; HYPERBILIRUBINEMIA; IMMUNOPRECIPITATION; INFLAMMATION; INTRAHEPATIC CHOLESTASIS; LIVER CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SEPSIS; TRANSACTIVATION; XENOBIOTIC METABOLISM; CYTOLOGY; DRUG EFFECT; GENETICS; LIVER; LIVER CELL CARCINOMA; METABOLISM; PHARMACOKINETICS; PHYSIOLOGY;

ACETYLATION; BILIRUBIN; CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION; GLUCOCORTICOIDS; HELA CELLS; HEPATOCYTES; HISTONES; HUMANS; INTERLEUKIN-1; LIPOPOLYSACCHARIDES; LIVER; NF-KAPPA B; PHARMACOKINETICS; PROMOTER REGIONS (GENETICS); RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTORS;

EID: 4644240254     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20387     Document Type: Article

References (50)

1. Andus T, Bauer J, Gerok W. Effects of cytokines on the liver. HEPATOLOGY 1991;13:364-375.
2. Morgan ET. Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev 1997;29:1129-1188.
3. Hill D, Shedlofsky S, McClain C, Diehl AM, Tsukamoto H. Cytokines and liver disease. In: Remick DG, Friedland, JS, Friedland JS, eds. Cytokines in health and disease. 2nd ed. New York: Marcel Dekker, 1997:401-425.
4. Cholerton S, Daly AK, Idle JR. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci 1992;13:434-439.
5. Abdel-Razzak Z, Corcos L, Fautrel A, Guillouzo A. Interleukin-1 beta antagonizes phenobarbital induction of several major cytochromes P450 in adult rat hepatocytes in primary culture. FEBS Lett 1995;366:159-164.
6. Beigneux AP, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. Reduction in cytochrome P-450 enzyme expression is associated with repression of CAR (constitutive androstane receptor) and PXR (pregnane X receptor) in mouse liver during the acute phase response. Biochem Biophys Res Commun 2002;293:145-149.
7. Li-Masters T, Morgan ET. Down-regulation of phenobarbital-induced cytochrome P4502B mRNAs and proteins by endotoxin in mice: independence from nitric oxide production by inducible nitric oxide synthase. Biochem Pharmacol 2002;64:1703-1711.
8. Muntane-Relat J, Ourlin JC, Domergue J, Maurel P. Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture. HEPATOLOGY 1995;22:1143-1153.
9. Pascussi JM, Gerbal-Chaloin S, Pichard-Garcia L, Daujat M, Fabre JM, Maurel P, et al. Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. Biochem Biophys Res Commun 2000;274:707-713.
10. Sewer MB, Morgan ET. Nitric oxide-independent suppression of P450 2C11 expression by interleukin-1beta and endotoxin in primary rat hepatocytes. Biochem Pharmacol 1997;54:729-737.
11. Trauner M, Fickert P, Stauber RE. Inflammation-induced cholestasis. J Gastroenterol Hepatol 1999;14:946-959.
12. Moseley RH. Sepsis-associated cholestasis. Gastroenterology 1997;112:302-306.
13. Bolder U, Ton-Nu HT, Schteingart CD, Frick E, Hofmann AF. Hepatocyte transport of bile acids and organic anions in endotoxemic rats: impaired uptake and secretion. Gastroenterology 1997;112:214-225.
14. Sueyoshi T, Kawamoto T, Zelko I, Honkakoski P, Negishi M. The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J Biol Chem 1999;274:6043-6046.
15. Gerbal-Chaloin S, Daujat M, Pascussi JM, Pichard-Garcia L, Vilarem MJ, Maurel P. Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor. J Biol Chem 2002; 277:209-217.
16. Goodwin B, Hodgson E, D'Costa DJ, Robertson GR, Liddle C. Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. Mol Pharmacol 2002;62:359-365.
17. Huang W, Zhang J, Chua SS, Qatanani M, Han Y, Granata R, et al. Induction of bilirubin clearance by the constitutive androstane receptor (CAR). Proc Natl Acad Sci U S A 2003;100:4156-4161.
18. Kast HR, Goodwin B, Tarr PT, Jones SA, Anisfeld AM, Stoltz CM, et al. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 2002;277:2908-2915.
19. Choi HS, Chung M, Tzameli I, Simha D, Lee YK, Seol W, et al. Differential transactivation by two isoforms of the orphan nucleat hormone receptor CAR. J Biol Chem 1997;272:23565-23571.
20. Zelko I, Negishi M. Phenobarbital-elicited activation of nuclear receptor CAR in induction of cytochrome P450 genes. Biochem Biophys Res Commun 2000;277:1-6.
21. Pascussi JM, Gerbal-Chaloin S, Fabre JM, Maurel P, Vilarem MJ. Dexamethasone enhances constitutive androstane receptor expression in human hepatocytes: consequences on cytochrome P450 gene regulation. Mol Pharmacol 2000;58:1441-1450.
22. Pascussi JM, Busson-Le Coniat M, Maurel P, Vilarem MJ. Transcriptional analysis of the orphan nuclear receptor constitutive androstane receptor (NR1I3) gene promoter: identification of a distal glucocorticoid response element. Mol Endocrinol 2003;17:42-55.
23. Reichardt HM, Tronche F, Berger S, Kellendonk C, Schutz G. New insights into glucocorticoid and mineralocorticoid signaling: lessons from gene targeting. Adv Pharmacol 2000;47:1-21.
24. Gustafsson JA, Carlstedt-Duke J, Poellinger L, Okret S, Wikstrom AC, Bronnegard M, et al. Biochemistry, molecular biology, and physiology of the glucocorticoid receptor. Endocr Rev 1987;8:185-234.
25. Gottlicher M, Heck S, Herrlich P. Transcriptional cross-talk, the second mode of steroid hormone receptor action. J Mol Med 1998;76:480-489.
26. Ray A, Prefontaine KE. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci U S A 1994;91:752-756.
27. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649-683.
28. Ghosh S. Regulation of inducible gene expression by the transcription factor NF-kappaB. Immunol Res 1999;19:183-189.
29. Karin M. How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene 1999;18:6867-6874.
30. Almawi WY, Melemedjian OK. Negative regulation of nuclear factor-kappaB activation and function by glucocorticoids. J Mol Endocrinol 2002;28:69-78.
31. Li-Masters T, Morgan ET. Effects of bacterial lipopolysaccharide on phenobarbital-induced CYP2B expression in mice. Drug Metab Dispos 2001; 29:252-257.
32. Gleeson D, Boyer JL. Intrahepatic cholestasis. In: McIntyre N, Benhamou J-P, Bircher J, Rizzetto M, Rodes J, eds. Oxford textbook of clinical hepatology. Oxford: Oxford Medical Publications, 1991:1087-1107.
33. Ke S, Rabson AB, Germino JF, Gallo MA, Tian Y. Mechanism of suppression of cytochrome P-450 1A1 expression by tumor necrosis factor-alpha and lipopolysaccharide. J Biol Chem 2001;276:39638-39644.
34. Basten GP, Bao Y, Williamson G. Sulforaphane and its glutathione conjugate but not sulforaphane nitrile induce UDP-glucuronosyl transferase (UGT1A1) and glutathione transferase (GSTA1) in cultured cells. Carcinogenesis 2002;23:1399-1404.
35. Wolffe AP. Transcriptional control. Sinful repression. Nature 1997;387:16-17.
36. Rundlett SE, Carmen AA, Suka N, Turner BM, Grunstein M. Transcriptional repression by UME6 involves deacetylation of lysine 5 of histone H4 by RPD3. Nature 1998;392:831-835.
37. Rodriguez-Ariza A, Paine AJ. Rapid induction of NF-kappaB binding during liver cell isolation and culture: inhibition by L-NAME indicates a role for nitric oxide synthase. Biochem Biophys Res Commun 1999;257:145-148.
38. Schiff L, Schiff ER. Diseases of the liver. 7th ed. Philadelphia: J.B. Lippincott Company, 1993:343-361.
39. Ikushiro S, Emi Y, Iyanagi T. Identification and analysis of drug-responsive expression of UDP-glucuronosyltransferase family 1 (UGT1) isozyme in rat hepatic microsomes using anti-peptide antibodies. Arch Biochem Biophys 1995;324:267-272.
40. Cunnings BS, Lasker JM, Lawrence HL. Expression of glutathione-dependent enzymes and cytochromes P450s in fresly isolated and primary cultures of proximal tubular cells from human kidney. J Pharmacol Exp Ther 2000;293:677-685.
41. Morel Y, Barouki R. Down-regulation of cytochrome P450 1A1 gene promoter by oxidative stress. Critical contribution of nuclear factor 1. J Biol Chem 1998;273:26969-26976.
42. Tinel M, Elkahwaji J, Robin MA, Fardel N, Descatoire V, Haouzi D, et al. Interleukin-2 overexpresses c-myc and down-regulates cytochrome P-450 in rat hepatocytes. J Pharmacol Exp Ther 1999;289:649-655.
43. Iber H, Chen Q, Cheng PY, Morgan ET. Suppression of CYP2C11 gene transcription by interleukin-1 mediated by NF-kappaB binding at the transcription start site. Arch Biochem Biophys 2000;377:187-194.
44. Jover R, Bort R, Gomez-Lechon MJ, Castell JV. Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved. FASEB J 2002;16:1799-1801.
45. Yaffe SJ, Levy G, Matsuzawa T, Baliah T. Enhancement of glucuronide-conjugating capacity in a hyperbilirubinemic infant due to apparent enzyme induction by phenobarbital. N Engl J Med 1966;275:1461-1466.
46. De Bosscher K, Vanden Berghe W, Vermeulen L, Plaisance S, Boone E, Haegeman G. Glucocorticoids repress NF-kappaB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc Natl Acad Sci U S A 2000;97:3919-3924.
47. Sheppard KA, Phelps KM, Williams AJ, Thanos D, Glass CK, Rosenfeld MG, et al. Nuclear integration of glucocorticoid receptor and nuclear factor-kappaB signaling by CREB-binding protein and steroid receptor coactivator-1. J Biol Chem 1998;273:29291-2924.
48. Ito K, Jazrawi E, Cosio B, Barnes PJ, Adcock IM. p65-activated histone acetyltransferase activity is repressed by glucocorticoids. J Biol Chem 2001; 276:30208-30215.
49. Roelofsen H, Schoemaker B, Bakker C, Ottenhoff R, Jansen PL, Elferink RP. Impaired hepatocanalicular organic anion transport in endotoxemic rats. Am J Physiol 1995;269:G427-G434.
50. Khatsenko O, Kikkawa Y. Nitric oxide differentially affects constitutive cytochrome P450 isoforms in rat liver. J Pharmacol Exp Ther 1997;280:1463-1470.